FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380884849> ?p ?o ?g. }

• W4380884849 endingPage "37" @default.
• W4380884849 startingPage "30" @default.
• W4380884849 abstract "The purpose of the article is to substantiate global trends in the research and innovation activities of multinational pharmaceutical companies and to identify key directions of transformation in corporate innovation strategies in the context of increased international competition in the global pharmaceutical market. Methodology. The methodological basis of the work is the following methods of scientific research: dialectical, historical-logical, system-structural analysis of economic processes and phenomena, analysis and synthesis, the method of quantitative and qualitative comparisons. Results. One of the key global sustainable development goals of the United Nations for the period up to 2030 is to ensure the health and well-being of nations, which in global terms can be achieved primarily on the basis of the large-scale research activities of multinational pharmaceutical companies and the systematic commercialisation of the results of corporate research and development. In recent decades, under the influence of technoglobalisation processes, the innovatisation of pharmaceutical companies' activities has accelerated. It finds its concentrated expression in the steady increase of R&D costs, diversification of their structure, mass commercialisation of innovative developments and strengthening of their transdisciplinarity, accelerated capitalisation of R&D costs, etc. According to the world experience, the most effective innovative strategies of pharmaceutical companies today are such as mergers and acquisitions, strategic alliances of pharmaceutical and biotechnology companies, innovative outsourcing and insourcing, cointegration and pseudo-concentration, corporatisation of patent portfolios and research technologies, venture financing of R&D of pharmaceutical companies. At the same time, mergers and acquisitions are increasing the capitalisation of the global pharmaceutical industry, strengthening its expansion into global markets, redistributing its regional segments and diversifying the sources of funding for pharmaceutical companies' research activities. Value/оriginality. Current trends and features of corporate strategy formation in multinational pharmaceutical companies are identified. Strategic orientations of research activities of pharmaceutical companies in specialised areas of clinical research in the context of therapeutic categories are determined. The process of capitalisation of pharmaceutical companies is analysed and the tendency to activate the use of corporate mergers and acquisitions (M&A) strategy in the pharmaceutical business is revealed. It is proposed to create strategic alliances of multifunctional pharmaceutical companies with biotech companies using the M&A strategy. It is recommended that pharmaceutical companies strengthen their innovation orientation in the design of their strategies by combining patent portfolios and research technologies, as well as jointly implementing large-scale innovation programmes and projects." @default.
• W4380884849 created "2023-06-17" @default.
• W4380884849 creator A5039165036 @default.
• W4380884849 creator A5065140372 @default.
• W4380884849 creator A5085971619 @default.
• W4380884849 date "2023-05-31" @default.
• W4380884849 modified "2023-09-25" @default.
• W4380884849 title "PRIORITY AREAS OF INNOVATION IN CORPORATE STRATEGIES OF MULTINATIONAL PHARMACEUTICAL COMPANIES IN GLOBAL COORDINATES" @default.
• W4380884849 cites W4249739469 @default.
• W4380884849 doi "https://doi.org/10.30525/2500-946x/2023-1-4" @default.
• W4380884849 hasPublicationYear "2023" @default.
• W4380884849 type Work @default.
• W4380884849 citedByCount "0" @default.
• W4380884849 crossrefType "journal-article" @default.
• W4380884849 hasAuthorship W4380884849A5039165036 @default.
• W4380884849 hasAuthorship W4380884849A5065140372 @default.
• W4380884849 hasAuthorship W4380884849A5085971619 @default.
• W4380884849 hasBestOaLocation W43808848491 @default.
• W4380884849 hasConcept C10138342 @default.
• W4380884849 hasConcept C136810230 @default.
• W4380884849 hasConcept C144133560 @default.
• W4380884849 hasConcept C150903083 @default.
• W4380884849 hasConcept C151730666 @default.
• W4380884849 hasConcept C158016649 @default.
• W4380884849 hasConcept C162324750 @default.
• W4380884849 hasConcept C162853370 @default.
• W4380884849 hasConcept C2779343474 @default.
• W4380884849 hasConcept C2779652045 @default.
• W4380884849 hasConcept C34447519 @default.
• W4380884849 hasConcept C40700 @default.
• W4380884849 hasConcept C46934059 @default.
• W4380884849 hasConcept C86803240 @default.
• W4380884849 hasConceptScore W4380884849C10138342 @default.
• W4380884849 hasConceptScore W4380884849C136810230 @default.
• W4380884849 hasConceptScore W4380884849C144133560 @default.
• W4380884849 hasConceptScore W4380884849C150903083 @default.
• W4380884849 hasConceptScore W4380884849C151730666 @default.
• W4380884849 hasConceptScore W4380884849C158016649 @default.
• W4380884849 hasConceptScore W4380884849C162324750 @default.
• W4380884849 hasConceptScore W4380884849C162853370 @default.
• W4380884849 hasConceptScore W4380884849C2779343474 @default.
• W4380884849 hasConceptScore W4380884849C2779652045 @default.
• W4380884849 hasConceptScore W4380884849C34447519 @default.
• W4380884849 hasConceptScore W4380884849C40700 @default.
• W4380884849 hasConceptScore W4380884849C46934059 @default.
• W4380884849 hasConceptScore W4380884849C86803240 @default.
• W4380884849 hasIssue "1" @default.
• W4380884849 hasLocation W43808848491 @default.
• W4380884849 hasOpenAccess W4380884849 @default.
• W4380884849 hasPrimaryLocation W43808848491 @default.
• W4380884849 hasRelatedWork W1927603792 @default.
• W4380884849 hasRelatedWork W1969442102 @default.
• W4380884849 hasRelatedWork W2071429584 @default.
• W4380884849 hasRelatedWork W2177860126 @default.
• W4380884849 hasRelatedWork W2273474069 @default.
• W4380884849 hasRelatedWork W2349871068 @default.
• W4380884849 hasRelatedWork W2355733707 @default.
• W4380884849 hasRelatedWork W2370103945 @default.
• W4380884849 hasRelatedWork W2376353976 @default.
• W4380884849 hasRelatedWork W2382609335 @default.
• W4380884849 hasVolume "8" @default.
• W4380884849 isParatext "false" @default.
• W4380884849 isRetracted "false" @default.
• W4380884849 workType "article" @default.